Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Understanding the pharmacokinetic (PK) and pharmacodynamic (PD) relationship of a therapeutic monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) exhibiting target‐mediated drug disposition (TMDD) is critical for selecting optimal dosing regimens. We describe the PK/PD...

詳細記述

保存先:
書誌詳細
出版年:J Clin Pharmacol
主要な著者: Gibbs, John P., Doshi, Sameer, Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Dodds, Michael G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Blom, Dirk
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2016
主題:
Pharmacokinetics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412926/
https://ncbi.nlm.nih.gov/pubmed/27861991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.840
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料